436 related articles for article (PubMed ID: 25901683)
1. TP53 loss creates therapeutic vulnerability in colorectal cancer.
Liu Y; Zhang X; Han C; Wan G; Huang X; Ivan C; Jiang D; Rodriguez-Aguayo C; Lopez-Berestein G; Rao PH; Maru DM; Pahl A; He X; Sood AK; Ellis LM; Anderl J; Lu X
Nature; 2015 Apr; 520(7549):697-701. PubMed ID: 25901683
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
3. A new way to target p53-defective colorectal cancer.
Liu Y; Wang L; Lu X
Future Oncol; 2015; 11(23):3101-4. PubMed ID: 26549592
[No Abstract] [Full Text] [Related]
4. Drug resistance and new therapies in colorectal cancer.
Van der Jeught K; Xu HC; Li YJ; Lu XB; Ji G
World J Gastroenterol; 2018 Sep; 24(34):3834-3848. PubMed ID: 30228778
[TBL] [Abstract][Full Text] [Related]
5. Colorectal cancer: POLR2A deletion with TP53 opens a window of opportunity for therapy.
Errico A
Nat Rev Clin Oncol; 2015 Jul; 12(7):374. PubMed ID: 25985938
[No Abstract] [Full Text] [Related]
6. Generation of an anti-EpCAM antibody and epigenetic regulation of EpCAM in colorectal cancer.
Liao MY; Kuo MY; Lu TY; Wang YP; Wu HC
Int J Oncol; 2015 Apr; 46(4):1788-800. PubMed ID: 25652097
[TBL] [Abstract][Full Text] [Related]
7. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.
Xu J; Liu Y; Li Y; Wang H; Stewart S; Van der Jeught K; Agarwal P; Zhang Y; Liu S; Zhao G; Wan J; Lu X; He X
Nat Nanotechnol; 2019 Apr; 14(4):388-397. PubMed ID: 30804480
[TBL] [Abstract][Full Text] [Related]
8. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
9. Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models.
Singh RK; Jones RJ; Shirazi F; Qin L; Zou J; Hong S; Wang H; Lee HC; Patel KK; Wan J; Choudhary RK; Kuiatse I; Pahl A; Orlowski RZ
Res Sq; 2024 Jan; ():. PubMed ID: 38260385
[TBL] [Abstract][Full Text] [Related]
10. CKIα ablation highlights a critical role for p53 in invasiveness control.
Elyada E; Pribluda A; Goldstein RE; Morgenstern Y; Brachya G; Cojocaru G; Snir-Alkalay I; Burstain I; Haffner-Krausz R; Jung S; Wiener Z; Alitalo K; Oren M; Pikarsky E; Ben-Neriah Y
Nature; 2011 Feb; 470(7334):409-13. PubMed ID: 21331045
[TBL] [Abstract][Full Text] [Related]
11. BRAF inhibition sensitizes melanoma cells to α-amanitin via decreased RNA polymerase II assembly.
Frischknecht L; Britschgi C; Galliker P; Christinat Y; Vichalkovski A; Gstaiger M; Kovacs WJ; Krek W
Sci Rep; 2019 May; 9(1):7779. PubMed ID: 31123282
[TBL] [Abstract][Full Text] [Related]
12. 8-Acetonyldihydronitidine inhibits the proliferation of human colorectal cancer cells via activation of p53.
Zhou J; Li Z; Zhang J; Wang H; Yin S; Du J
Eur J Pharmacol; 2019 Jul; 854():256-264. PubMed ID: 30928633
[TBL] [Abstract][Full Text] [Related]
13. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
14. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
15. Enhancing the Pharmacokinetics and Antitumor Activity of an α-Amanitin-Based Small-Molecule Drug Conjugate via Conjugation with an Fc Domain.
Gallo F; Korsak B; Müller C; Hechler T; Yanakieva D; Avrutina O; Kolmar H; Pahl A
J Med Chem; 2021 Apr; 64(7):4117-4129. PubMed ID: 33755471
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53.
Yoon H; Liyanarachchi S; Wright FA; Davuluri R; Lockman JC; de la Chapelle A; Pellegata NS
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15632-7. PubMed ID: 12438652
[TBL] [Abstract][Full Text] [Related]
17. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
[TBL] [Abstract][Full Text] [Related]
18. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.
Liu Y; Chen C; Xu Z; Scuoppo C; Rillahan CD; Gao J; Spitzer B; Bosbach B; Kastenhuber ER; Baslan T; Ackermann S; Cheng L; Wang Q; Niu T; Schultz N; Levine RL; Mills AA; Lowe SW
Nature; 2016 Mar; 531(7595):471-475. PubMed ID: 26982726
[TBL] [Abstract][Full Text] [Related]
19. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.
Inoue A; Robinson FS; Minelli R; Tomihara H; Rizi BS; Rose JL; Kodama T; Srinivasan S; Harris AL; Zuniga AM; Mullinax RA; Ma X; Seth S; Daniele JR; Peoples MD; Loponte S; Akdemir KC; Khor TO; Feng N; Roszik J; Sobieski MM; Brunell D; Stephan C; Giuliani V; Deem AK; Shingu T; Deribe YL; Menter DG; Heffernan TP; Viale A; Bristow CA; Kopetz S; Draetta GF; Genovese G; Carugo A
Gastroenterology; 2021 Jul; 161(1):196-210. PubMed ID: 33745946
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
